NCT05038436View on ClinicalTrials.gov

Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions
Cholesterol Lowering
Interventions
DEVICE

Polyglucosamine L112

Two tablets once daily per os

Trial Locations (1)

53227

Phase I-Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn

Sponsors
All Listed Sponsors
collaborator

University Hospital, Bonn

OTHER

lead

Certmedica International GmbH

INDUSTRY

NCT05038436 - Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption | Biotech Hunter | Biotech Hunter